Eisai's Lenvima passes Phase III HCC test

Eisai Co. Ltd. (Tokyo:4523) said Lenvima lenvatinib showed non-inferiority to Nexavar sorafenib in the Phase III Study 304 to treat hepatocellular carcinoma (HCC), meeting its primary endpoint of overall survival.

The trial examined 954 patients with unresectable HCC receiving either drug in the first-line setting. Eisai said Lenvima also led to significant improvements on secondary endpoints of progression-free survival (PFS), time to progression and objective response rate (ORR). Patients received 8 or 12 mg Lenvima depending on body weight...